Skip to main content
Premium Trial:

Request an Annual Quote

Pairings: Jul 14, 2010


Myriad Genetics announced last week the appointment of Gary King to the newly created position of executive vice president of international operations. King will oversee Myriad's expansion into Europe and other international markets. His immediate focus will be commercializing Myriad's eight diagnostic products in major market countries of Germany, France, Italy, Spain, and the United Kingdom, the company said.

Prior to joining Myriad, King was CEO of the international biotech firm AverDx. King also served as the VP of international operations at Biosite and as division director in Japan for Guidant.

The Scan

Panel Votes for COVID-19 Pill

A US Food and Drug Administration panel has voted to support the emergency use authorization of an antiviral pill for COVID-19 from Merck and Ridgeback Biotherapeutics, CNN says.

But Not Harm

New Scientist reports that UK bioethicists say that though gene editing may improve food production, it should not harm livestock welfare.

Effectiveness Drop Anticipated

Moderna's Stéphane Bancel predicts that that current SARS-CoV-2 vaccines may be less effective against the Omicron variant, the Financial Times reports.

Cell Studies of Human Chromatin Accessibility, SARS-CoV-2 Variants, Cell Signaling Networks

In Cell this week: chromatin accessibility maps of adult human tissues, modeling to track SARS-CoV-2 variants of concern, and more.